FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2790276829> ?p ?o ?g. }

• W2790276829 endingPage "11571" @default.
• W2790276829 startingPage "11559" @default.
• W2790276829 abstract "5-FU is used as the main backbone of chemotherapy regimens for patients with colorectal and other gastrointestinal cancers. Despite development of new strategies that allowed enhancing clinical effectiveness and tolerability of 5-FU, 10-30% of patients treated with 5-FU-based regimens experience severe treatment-related toxicity. In our study, we evaluated the 5-FU exposure-toxicity relationship and investigated the efficacy of PK-guided dosing in increasing tolerability of 5-FU-based chemotherapy.50.7% of patients required dose adjustments after cycle 1. Percentage of patients within 5-FU AUC range was 49.3%, 66.9%, 61.0% at cycle 1, 2 and 3 respectively (p = 0.002 cycle 1 vs cycle 2). At all 3 cycles, lower incidences of grade I/II toxicities were observed for patients below or within range compared with those above range (19.4% vs 41.3%, p < 0.001 respectively).Our analysis confirms that the use of BSA-guided dosing results in highly variable 5-FU exposure and strongly suggests that PK-guided dosing can improve tolerability of 5-FU based chemotherapy in patients with gastrointestinal cancers, thus supporting 5-FU therapeutic drug monitoring.155 patients with gastrointestinal cancers, who were to receive 5-FU-based regimens were included in our study. At cycle 1, the 5-FU dose was calculated using patient's Body Surface Area (BSA) method. A blood sample was drawn on Day 2 to measure 5-FU concentration. At cycle 2, the 5-FU dose was adjusted using a PK-guided dosing strategy targeting a plasma AUC range of 18-28 mg·h/L, based on cycle 1 concentration. Assessments of toxicity was performed at the beginning of every cycle." @default.
• W2790276829 created "2018-03-29" @default.
• W2790276829 creator A5000760104 @default.
• W2790276829 creator A5020083980 @default.
• W2790276829 creator A5041771579 @default.
• W2790276829 creator A5043463827 @default.
• W2790276829 creator A5044685406 @default.
• W2790276829 creator A5060736240 @default.
• W2790276829 creator A5070203004 @default.
• W2790276829 creator A5078065507 @default.
• W2790276829 creator A5086294065 @default.
• W2790276829 creator A5088504217 @default.
• W2790276829 date "2018-01-30" @default.
• W2790276829 modified "2023-10-16" @default.
• W2790276829 title "5-FU therapeutic drug monitoring as a valuable option to reduce toxicity in patients with gastrointestinal cancer" @default.
• W2790276829 cites W1774948393 @default.
• W2790276829 cites W1844681537 @default.
• W2790276829 cites W1970054935 @default.
• W2790276829 cites W1977980459 @default.
• W2790276829 cites W1995540899 @default.
• W2790276829 cites W2000966102 @default.
• W2790276829 cites W2006569509 @default.
• W2790276829 cites W2009388286 @default.
• W2790276829 cites W2021324583 @default.
• W2790276829 cites W2028100471 @default.
• W2790276829 cites W2032031944 @default.
• W2790276829 cites W2047544514 @default.
• W2790276829 cites W2057975842 @default.
• W2790276829 cites W2067463615 @default.
• W2790276829 cites W2074706593 @default.
• W2790276829 cites W2085512302 @default.
• W2790276829 cites W2090651425 @default.
• W2790276829 cites W2103766921 @default.
• W2790276829 cites W2123839142 @default.
• W2790276829 cites W2130648260 @default.
• W2790276829 cites W2133475948 @default.
• W2790276829 cites W2138684147 @default.
• W2790276829 cites W2142287269 @default.
• W2790276829 cites W2142616277 @default.
• W2790276829 cites W2156599794 @default.
• W2790276829 cites W2166076052 @default.
• W2790276829 cites W2166277894 @default.
• W2790276829 cites W2173822384 @default.
• W2790276829 cites W2177197858 @default.
• W2790276829 cites W2267854900 @default.
• W2790276829 cites W2274849119 @default.
• W2790276829 cites W2296046501 @default.
• W2790276829 cites W2316688895 @default.
• W2790276829 cites W2360224810 @default.
• W2790276829 cites W2396699631 @default.
• W2790276829 cites W2406430468 @default.
• W2790276829 cites W2419577768 @default.
• W2790276829 cites W2463828422 @default.
• W2790276829 cites W2606453095 @default.
• W2790276829 cites W2749779586 @default.
• W2790276829 cites W4250481919 @default.
• W2790276829 cites W2616097126 @default.
• W2790276829 doi "https://doi.org/10.18632/oncotarget.24338" @default.
• W2790276829 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5837758" @default.
• W2790276829 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29545919" @default.
• W2790276829 hasPublicationYear "2018" @default.
• W2790276829 type Work @default.
• W2790276829 sameAs 2790276829 @default.
• W2790276829 citedByCount "40" @default.
• W2790276829 countsByYear W27902768292018 @default.
• W2790276829 countsByYear W27902768292019 @default.
• W2790276829 countsByYear W27902768292020 @default.
• W2790276829 countsByYear W27902768292021 @default.
• W2790276829 countsByYear W27902768292022 @default.
• W2790276829 countsByYear W27902768292023 @default.
• W2790276829 crossrefType "journal-article" @default.
• W2790276829 hasAuthorship W2790276829A5000760104 @default.
• W2790276829 hasAuthorship W2790276829A5020083980 @default.
• W2790276829 hasAuthorship W2790276829A5041771579 @default.
• W2790276829 hasAuthorship W2790276829A5043463827 @default.
• W2790276829 hasAuthorship W2790276829A5044685406 @default.
• W2790276829 hasAuthorship W2790276829A5060736240 @default.
• W2790276829 hasAuthorship W2790276829A5070203004 @default.
• W2790276829 hasAuthorship W2790276829A5078065507 @default.
• W2790276829 hasAuthorship W2790276829A5086294065 @default.
• W2790276829 hasAuthorship W2790276829A5088504217 @default.
• W2790276829 hasBestOaLocation W27902768291 @default.
• W2790276829 hasConcept C112705442 @default.
• W2790276829 hasConcept C121608353 @default.
• W2790276829 hasConcept C126322002 @default.
• W2790276829 hasConcept C143998085 @default.
• W2790276829 hasConcept C197934379 @default.
• W2790276829 hasConcept C19831878 @default.
• W2790276829 hasConcept C2776694085 @default.
• W2790276829 hasConcept C2777288759 @default.
• W2790276829 hasConcept C2778375690 @default.
• W2790276829 hasConcept C2780035454 @default.
• W2790276829 hasConcept C2780272996 @default.
• W2790276829 hasConcept C29730261 @default.
• W2790276829 hasConcept C526805850 @default.
• W2790276829 hasConcept C542804219 @default.
• W2790276829 hasConcept C71924100 @default.
• W2790276829 hasConcept C90924648 @default.

• next